Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

J&J’s Anti-IL-23 Guselkumab Phase III-Ready After Solid Psoriasis Results

Apr 22 2014

• By Emily Hayes

Related Content

Janssen R&D’s Immunology Unit Grounded In Translational Thinking

Mar 01 2012

Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into

Jul 23 2012

J&J Highlights Late-Stage R&D Prospects Across Pharma Division

Jun 03 2013

J&J’s Solid Launches Lead Strong Pharma Segment Quarter

Jul 16 2013

Related Companies

Johnson & Johnson

Johnson & Johnson

MorphoSys AG

AbbVie Inc.

Johnson & Johnson

GSK plc

Astellas Pharma, Inc.

Merck & Co., Inc.

Additional Topics

Clinical Trials BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window